ConductScience.org, home

Paper21366473

Long-term effects of intensive glucose lowering on cardiovascular outcomes.

ACCORD Study Group and 14 others. N Engl J Med, 2011. Cited by 765 papers, by iCite.

Cite this record

ConductScience Library. Long-term effects of intensive glucose lowering on cardiovascular outcomes. Papers, record 21366473. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21366473

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Long-term effects of intensive glucose lowering on cardiovascular outcomes.
PubMed
Journal
N Engl J Med
PubMed
Year
2011
PubMed
Publication types
Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
765
iCite
Relative citation ratio, by iCite
21.4
iCite
Revised in PubMed
2026-05-18
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1ACCORD Study GroupGroup
2Gerstein HCHertzel C
3Miller MEMichael E
4Genuth SSaul
5Ismail-Beigi FFaramarz
6Buse JBJohn B
7Goff DC JrDavid C
8Probstfield JLJeffrey L
9Cushman WCWilliam C
10Ginsberg HNHenry N
11Bigger JTJ Thomas
12Grimm RH JrRichard H
13Byington RPRobert P
14Rosenberg YDYves D
15Friedewald WTWilliam T

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cardiovascular DiseasesMajor topic
Diabetes Mellitus, Type 2Major topic
Glycated HemoglobinMajor topic
Hypoglycemic AgentsMajor topic
Adult
Aged
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Myocardial Infarction
Proportional Hazards Models
Stroke
Treatment Outcome

Source PubMed

Download CSV of topics

Grants21

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
N01 HC095179NHLBI NIH HHSUnited StatesN01HC095179PubMed and NIHNIH RePORTER
N01 HC095184NHLBI NIH HHSUnited StatesN01HC095184PubMed and NIHNIH RePORTER
N01-HC-95180NHLBI NIH HHSUnited StatesN01HC095180PubMed and NIHNIH RePORTER
N01 HC095178NHLBI NIH HHSUnited StatesN01HC095178PubMed and NIHNIH RePORTER
Y1-HC-1010NHLBI NIH HHSUnited StatesPubMedPubMed
N01-HC-95184NHLBI NIH HHSUnited StatesN01HC095184PubMed and NIHNIH RePORTER
N01 HC095182NHLBI NIH HHSUnited StatesN01HC095182PubMed and NIHNIH RePORTER
N01-HC-95183NHLBI NIH HHSUnited StatesN01HC095183PubMed and NIHNIH RePORTER
N01-HC-95178NHLBI NIH HHSUnited StatesN01HC095178PubMed and NIHNIH RePORTER
N01-HC-95179NHLBI NIH HHSUnited StatesN01HC095179PubMed and NIHNIH RePORTER
N01-HC-95181NHLBI NIH HHSUnited StatesN01HC095181PubMed and NIHNIH RePORTER
Y1-HC-9035NHLBI NIH HHSUnited StatesPubMedPubMed
N01 HC095178NHLBI NIH HHSUnited StatesN01HC095178PubMed and NIHNIH RePORTER
N01 HC095180NHLBI NIH HHSUnited StatesN01HC095180PubMed and NIHNIH RePORTER
Y01 HC001010NHLBI NIH HHSUnited StatesY01HC001010PubMedNIH RePORTER
Y01 HC009035NHLBI NIH HHSUnited StatesY01HC009035PubMedNIH RePORTER
N01 HC095181NHLBI NIH HHSUnited StatesN01HC095181PubMed and NIHNIH RePORTER
N01-HC-95182NHLBI NIH HHSUnited StatesN01HC095182PubMed and NIHNIH RePORTER
N01 HC095183NHLBI NIH HHSUnited StatesN01HC095183PubMed and NIHNIH RePORTER
R43HL095181NIHNIH RePORTER

See all 21 grantsDownload CSV of grants

Trials4

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00000620Action to Control Cardiovascular Risk in Diabetes (ACCORD)Derived from the trialYesClinicalTrials.gov
NCT01945268Influenza Vaccine To Prevent Adverse Vascular Events:PilotBackgroundClinicalTrials.gov
NCT02762851Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE)BackgroundClinicalTrials.gov
NCT03700645Allopurinol in Diabetes Mellitus and Multivessel Coronary Artery DiseaseBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections5

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in21544049Diabetes: ACCORD: 5-year outcomes of intensive glycemic control.https://conductscience.org/library/papers/21544049PubMed
Comment in21576520ACP journal club. Intensive glucose control increased mortality and did not prevent CV events compared with standard glucose control in type 2 diabetes.https://conductscience.org/library/papers/21576520PubMed
Comment in21651403Intensive glucose lowering and cardiovascular outcomes.https://conductscience.org/library/papers/21651403PubMed
Comment in21651404Intensive glucose lowering and cardiovascular outcomes.https://conductscience.org/library/papers/21651404PubMed
Comment in22106337Intensive glucose lowering (HbA1c target<6.0%) for people with type 2 diabetes increases mortality.https://conductscience.org/library/papers/22106337PubMed

Download CSV of comments and corrections

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120228401Effects of intensive blood-pressure control in type 2 diabetes mellitus.N Engl J Med2010https://conductscience.org/library/papers/20228401PubMed
220228404Effects of combination lipid therapy in type 2 diabetes mellitus.N Engl J Med2010https://conductscience.org/library/papers/20228404PubMed
320061360
The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.
BMJ2010https://conductscience.org/library/papers/20061360PubMed
418539917Effects of intensive glucose lowering in type 2 diabetes.N Engl J Med2008https://conductscience.org/library/papers/18539917PubMed
517599423Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.Am J Cardiol2007https://conductscience.org/library/papers/17599423PubMed
620103550Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.Diabetes Care2010https://conductscience.org/library/papers/20103550PubMed
718695086
The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.
Arch Intern Med2008https://conductscience.org/library/papers/18695086PubMed
820200384Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults.N Engl J Med2010https://conductscience.org/library/papers/20200384PubMed
91878409010-year follow-up of intensive glucose control in type 2 diabetes.N Engl J Med2008https://conductscience.org/library/papers/18784090PubMed
1020427682Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.Diabetes Care2010https://conductscience.org/library/papers/20427682PubMed
1120061358The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.BMJ2010https://conductscience.org/library/papers/20061358PubMed
1218043905HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women.Diabetologia2008https://conductscience.org/library/papers/18043905PubMed
1316371403Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies.BMJ2006https://conductscience.org/library/papers/16371403PubMed
1420008761Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study.Ann Intern Med2009https://conductscience.org/library/papers/20008761PubMed
1516157837Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study.Arch Intern Med2005https://conductscience.org/library/papers/16157837PubMed

Download CSV of references

Cited by389

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 765 citations.

PMIDTitleJournalYearIn PapersSource
42568448Prognostic value of the cardiometabolic index for cardiovascular outcomes in patients with type 2 diabetes mellitus.Front Nutr2026https://conductscience.org/library/papers/42568448PubMed
42471914Associations of glycated hemoglobin with etiology, lesions, and outcome of ischemic stroke: Japan Stroke Data Bank.eNeurologicalSci2026https://conductscience.org/library/papers/42471914PubMed
42375334Intensive blood pressure control in type 2 diabetes: a meta-analysis of randomized controlled trials.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42375334PubMed
41827204Diabetes Mellitus as an Integrated Microbiome, Immune, and Metabolic Disorder with Clinical Implications for Multisystem Complications and Public Health.J Clin Med2026https://conductscience.org/library/papers/41827204PubMed
41622209Association of fenofibrate therapy with cardiovascular events and mortality in diabetes patients with early-diagnosed hyperlipidemia.Lipids Health Dis2026https://conductscience.org/library/papers/41622209PubMed
41489606Trained Immunity and Cardiovascular Risk: An Immunological Perspective.Immunol Rev2026https://conductscience.org/library/papers/41489606PubMed
41459091BRI shows stronger association than BMI for MACE in patients with T2DM: insights from the ACCORD study.Front Nutr2025https://conductscience.org/library/papers/41459091PubMed
41408264Associations and predictive value of weight-adjusted waist index for cardiovascular outcomes in type 2 diabetes: evidence from the ACCORD study.Nutr J2025https://conductscience.org/library/papers/41408264PubMed
41243295Bridging Evidence and Practice: A Consensus Statement from the Korean Diabetes Association on Diabetes Screening, Pharmacological Treatment and Severe Diabetes.Diabetes Metab J2025https://conductscience.org/library/papers/41243295PubMed
41127917Development of a Novel Machine Learning Method for Estimation of Life-Long Chronic Disease Progression and Its Application to Type 2 Diabetes.Clin Transl Sci2025https://conductscience.org/library/papers/41127917PubMed
41078062Depressive symptoms and hypoglycaemic risk in individuals with type 2 diabetes mellitus: insights from the ACCORD-HRQL study.BJPsych Open2025https://conductscience.org/library/papers/41078062PubMed
41071620Joslin Kidney Panel of Circulating Proteins: A Tool for ESKD Risk Discrimination and Individualized Diabetic Kidney Disease Treatment.Clin J Am Soc Nephrol2026https://conductscience.org/library/papers/41071620PubMed
40933374Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes mellitus: a meta-analysis.Front Endocrinol (Lausanne)2025https://conductscience.org/library/papers/40933374PubMed
40868889Immune Dysregulation Connecting Type 2 Diabetes and Cardiovascular Complications.Life (Basel)2025https://conductscience.org/library/papers/40868889PubMed
40837332Triglyceride glucose-body mass index is associated with cardiovascular outcomes and overall mortality in type-2 diabetes mellitus patients.World J Diabetes2025https://conductscience.org/library/papers/40837332PubMed
40782797Inflammation reprogramming and immunomodulation: Next-generation treatments for atherosclerosis.Cell Rep Med2025https://conductscience.org/library/papers/40782797PubMed
40712766Diabetic Retinopathy Incidence, Progression, and Health-Related Quality of Life From the ACCORD Trial.Am J Ophthalmol2025https://conductscience.org/library/papers/40712766PubMed
40674363Association between estimated glucose disposal rate and major adverse cardiovascular events in patients with type 2 diabetes.PLoS One2025https://conductscience.org/library/papers/40674363PubMed
40628839Association and predictive value of the triglyceride glucose-weight adjusted waist index for cardiovascular outcomes in patients with type 2 diabetes.Sci Rep2025https://conductscience.org/library/papers/40628839PubMed
40603602PowerAI-Diabetes: Review of glycemic and lipid variability to predict cardiovascular events in Chinese diabetic population.NPJ Metab Health Dis2024https://conductscience.org/library/papers/40603602PubMed

See all 389 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630

Source NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
SIMVASTATINCHEMBL1064Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1064ChEMBL
FENOFIBRATECHEMBL672Derived from the trial1https://conductscience.org/library/drugs/CHEMBL672ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21366473

GET https://conductscience.org/api/papers/v1/21366473/grants?page=2